Dear BioClonetics Investor and Wefunders, 

We wish everyone a very Happy New Year and are excited about our prospects for progress in 2018.

We have today opened a new funding round on www.startengine.com/bioclonetics and we ask each of you to look at this campaign and share it with one friend to examine our technology for finding a cure for HIV using our monoclonal antibody technology.  Funds from this fundraising round will be used in the testing and further development of the recombinant antibody that is now being produced.

Here is our status and current progress. 

As we have reported, we are continuing the development of our monoclonal antibody (called Clone 3) that has been demonstrated through testing in 5 laboratories to neutralize the HIV virus. The results of these tests demonstrating the neutralizing capability against multiple different strains of the virus are shown on our website at http://www.bioclonetics.com/validation.html.

We are now producing the recombinant form of the antibody – which is required by the FDA for use in patient therapy. Once produced, we will test this recombinant form against numerous strains of the HIV virus and then confirm efficacy in tests in animal and clinical trials.

To prepare the recombinant for testing, we have engaged 2 primary labs (one in New England and one in New Jersey/Shanghai China).  Since my last update, additional information has been established as to the precise amino acid sequence needed to produce the recombinant. The full sequence is still not yet determined but additional analysis is under way to confirm the full sequence. Without regard to whether these few illusive elements are identified, we are moving forward to product multiple recombinants with varying sequences - each of which will be tested to determine efficacy.

Let me analogize in a way that might be less technical and more easily understood.  Assume you have a favorite award winning dessert made by your mother that you wish to reproduce.  She cannot give you the full list of ingredients and you set out to reverse analyze the one dessert she has made to determine the list of ingredients. You know that the recipe has 1346 ingredients (this corresponds to the 1346 amino acids making up our parent antibody).  Of these 1346 ingredients, you know 1339 and are trying to identify the remaining few. You can continue to search for these 7 or you might make multiple desserts with (1) leaving out the 7 unknown ingredients, (2) substituting your best educated guess at to the unknown ingredients, or (3) make multiple desserts with multiple alternating ingredients.  We are doing all 3.

Once you have make the dessert, you would test it - in the dessert case, you would taste test or otherwise evaluate your final product.  In our case, the recombinants will be tested for binding to HIV viruses and then tested against multiple strains of the virus. 

Additionally, we are continuing our discussions with a global non-profit organization whose sole focus in on the development of a treatment and vaccine against HIV. Our monoclonal is one under consideration for further development by this organization. This is a promising opportunity and will be fully explored in the New Year although our current effort is going forward without any delay.  Your contribution is making our progress possible.

We will keep you informed of our progress but rest assured that we are moving forward with each day.

Best wishes,
Charles Cotropia
CEO - BioClonetics Immunotherapeutics, Inc.